Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial
In the article entitled “Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial” (1), the affiliation of Fengrui Xu should be corrected as follows: 1Department of Breast Oncology, Academy of Military Medical Sciences, Beijing 100089, China; 2Department of Breast Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China
We regret the errors.
References
- 1.Xu F, Zhang Y, Miao Z, et al. Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial. Ann Transl Med 2019;7:482. 10.21037/atm.2019.07.95 [DOI] [PMC free article] [PubMed] [Google Scholar]